Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Disc Medicine, Inc. Common Stock (IRON)

Pharmaceutical Preparations

https://www.discmedicine.com

Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firm's pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism.

321 ARSENAL STREET, SUITE 101
WATERTOWN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/08/2021

Market Cap

1,409,894,694

Shares Outstanding

24,140,000

Weighted SO

24,140,428

Total Employees

N/A

Upcoming Earnings

08/09/2024

Similar Tickers

ANEB --.--%

ADAG --.--%

ACRV --.--%

ANAB --.--%

MLYS --.--%

OLMA --.--%

LRMR --.--%

FENC --.--%

OBIO --.--%

Beta

0.1820

Last Div

0.0000

Range

25.6-77.6

Chg

-0.8900

Avg Vol

360948

Mkt Cap

1409894694

Exch

NASDAQ

Country

US

Phone

617 674 9274

DCF Diff

32.2650

DCF

16.0550

Div Yield

0.0000

P/S

0.0000

EV Multiple

-8.2132

P/FV

2.4887

Div Yield %

0.0000

P/E

-13.3682

PEG

-0.1449

Payout

0.0000

Current Ratio

25.0242

Quick Ratio

25.0242

Cash Ratio

24.6649

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

22807.6974

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0013

ROA

-0.1784

ROE

-0.2378

ROCE

-0.2265

NI/EBT

1.0013

EBT/EBIT

0.8189

EBIT/Rev

0.0000

Debt Ratio

0.0021

D/E

0.0022

LT Debt/Cap

0.0022

Total Debt/Cap

0.0022

Int Coverage

0.0000

CF/Debt

-54.6256

Equity Multi

1.0438

Rec Turnover

0.0000

Pay Turnover

0.0160

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-2.2959

FCF/Share

-2.3003

Cash/Share

28.1191

OCF/Sales

0.0000

FCF/OCF

1.0020

CF Coverage

-54.6256

ST Coverage

0.0000

CapEx Coverage

-512.0689

Div&CapEx Cov

-512.0689

P/BV

2.4887

P/B

2.4887

P/S

0.0000

P/E

-13.3682

P/FCF

-23.8960

P/OCF

-20.6590

P/CF

-20.6590

PEG

-0.1449

P/S

0.0000

EV Multiple

-8.2132

P/FV

2.4887

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 23, 02:35 Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire Inc. Jan 03, 17:00 Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 22, 11:06 Biotech stocks set for a rebound in 2024, analysts say GlobeNewswire Inc. Dec 20, 16:30 Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board GlobeNewswire Inc. Dec 11, 20:30 Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting GlobeNewswire Inc. Dec 11, 20:30 Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting GlobeNewswire Inc. Dec 11, 20:30 Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting GlobeNewswire Inc. Nov 14, 16:44 Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin GlobeNewswire Inc. Nov 08, 16:30 Disc Medicine to Participate in Upcoming Investor Conferences

Revenue Product Segmentation